Clinical cornerstone最新文献_第4页

CME Test Questions CME考试问题

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-11-29 DOI: 10.1016/S1098-3597(08)60031-9

引用次数: 0

CME test questions therapeutic options for cardiometabolic risk factors CME测试对心脏代谢危险因素的治疗选择提出疑问

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-07-15 DOI: 10.1016/S1098-3597(08)80006-3

引用次数: 0

CME Test Answer Sheet and Evaluation Form for Abdominal Adiposity: An Emerging Marker of Cardiometabolic Risk Volume 9, Number 1 腹部肥胖的CME测试答卷和评估表格:心脏代谢风险的新兴标志第9卷，第1号

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-11-29 DOI: 10.1016/S1098-3597(08)60032-0

引用次数: 0

CME test answers therapeutic options for cardiometabolic risk factors CME测试回答心脏代谢危险因素的治疗选择

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-07-15 DOI: 10.1016/S1098-3597(08)80008-7

引用次数: 0

CME Information 芝加哥商品交易所的信息

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2009-05-02 DOI: 10.1016/S1098-3597(09)60019-3

引用次数: 0

Commentary on Current Literature 当代文学评论

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-11-29 DOI: 10.1016/S1098-3597(08)60029-0

Richard A. Johnson MD

引用次数: 37

Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management 2型糖尿病的高血糖、高血压和血脂异常:糖尿病管理的目标

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2009-05-02 DOI: 10.1016/S1098-3597(09)60021-1

Derek LeRoith MD, PhD

{"title":"Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management","authors":"Derek LeRoith MD, PhD","doi":"10.1016/S1098-3597(09)60021-1","DOIUrl":"10.1016/S1098-3597(09)60021-1","url":null,"abstract":"<div>Type 2 diabetes mellitus (DM) is frequently associated with other major cardiovascular risk factors, namely, hypertension and hypertriglyceridemia; low levels of high-density lipoprotein cholesterol and elevated levels of low-density lipoprotein cholesterol; the likely presence of metabolic syndrome; and the spectrum of nontraditional risk factors, including inflammation, hypercoagulability, and vascular endothelial abnormalities, that often accompany insulin resistance. Patients with type 2 DM, therefore, are at an increased risk for cardiovascular disease (CVD) and mortality. Along with the prevention of microvascular complications, the prevention of CVD events and mortality are major goals of diabetes therapy. Research has helped to establish targets for the treatment of the 3 major risk factors for type 2 DM–hypertension, hyperglycemia, and dyslipidemia—and clinical guidelines agree about the need to monitor and treat these risk factors. Lifestyle modification is recommended as a first-line approach to risk reduction; however, many patients will also require pharmacotherapy to achieve their treatment goals.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"9 ","pages":"Pages S8-S16"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(09)60021-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56553781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

CME test answers CME考试答案

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-08-16 DOI: 10.1016/S1098-3597(08)80017-8

引用次数: 0

CME Information Therapeutic options for cardiometabolic risk factors 心血管代谢危险因素的治疗选择

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-07-15 DOI: 10.1016/S1098-3597(08)80001-4

引用次数: 0

Obesity-Related Cardiometabolic Complications 肥胖相关的心脏代谢并发症

Clinical cornerstone Pub Date : 2008-01-01 Epub Date: 2008-11-29 DOI: 10.1016/S1098-3597(08)60024-1

Christopher P. Cannon MD

{"title":"Obesity-Related Cardiometabolic Complications","authors":"Christopher P. Cannon MD","doi":"10.1016/S1098-3597(08)60024-1","DOIUrl":"10.1016/S1098-3597(08)60024-1","url":null,"abstract":"<div>Obese patients are at increased risk for developing numerous cardiometabolic complications, including hypertension, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease (CVD). These complications are associated with an increase in mortality and appear to be related to the changes in adipocytcs that occur with obesity. The enlarged adipocytes found in obese individuals release more glycerol, free fatty acids, and proinflammatory factors and less adiponectin. Some of these changes result in insulin resistance, which appears to be integral to the development of the obesity-associated cardiometabolic complications. Weight loss and increased physical activity are key to reducing the risk for obese individuals to develop cardiovascular complications. However, many patients also require drug therapy. Because many obese patients have multiple cardiometabolic complications, ideally, drug therapy that has positive effects on multiple CVD risk factors should be used. Therapies directed at obesity, such as sibutramine and endocannabinoid receptor blockers (eg, rimonabant), have shown improvements in weight, blood pressure, the lipid profile, and glucose levels.</div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"9 1","pages":"Pages 11-22"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(08)60024-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27871248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22